麻豆果冻传媒影音

High response rates out to 52 weeks with IL-23 inhibitor, correlating with eradication of T cells

Itch, sleep disturbance, lesion healing, quality of life improved substantially in most patients

Noninferiority achieved across all skin subtypes

At least 50% reduction in abscess, nodule count at 16 weeks for more than 70% of patients

Almost 40% of patients had no more than one active lesion after 12 weeks of berdazimer gel

Rapid reduction in itch, sleep disturbance, nodules after first dose of nemolizumab

Responses often maintained after drug withdrawal, long-term persistence with ongoing treatment

Rates of 90% clearance approaching 50% at 12 weeks, with 100% clearance rates as high as 33%

Disease status, itch improved significantly within 1 to 2 weeks with roflumilast cream

New analyses show "unprecedented" rates of 50% to 100% improvement

About 40% of patients go from nearly hairless to almost a full head of hair with deuruxolitinib

"Dramatic improvement" at 16 weeks with IL-23 blocker after lack of response to anti-IL-17 drug

AAD data also promising for therapies in psoriasis, pyoderma gangrenosum

No reduction in vascular inflammation with apremilast but significant reduction in body fat